Critical Path Institute (C-Path) has appointed Klaus Romero, M.D., M.S., FCP, as its new Chief Executive Officer and has promoted Cécile Ollivier, M.S., from former Managing Director for Europe to Vice President of International Affairs.
With an impressive tenure spanning more than 16 years at C-Path, Dr. Romero has held key positions within the organization, including Chief Scientific Officer and Executive Director of Clinical Pharmacology and Quantitative Medicine Program. His critical role in creating and leading the Quantitative Medicine program underscores his significant contributions to C-Path’s critical drug development initiatives over the years.
Commenting on the appointment, Mr. Wainwright Fishburn, Jr., Chairman of the Board of Directors of C-Path, said, “Dr. Romero’s exceptional expertise and leadership have been instrumental in our journey to create and implement groundbreaking scientific and regulatory pathways. His strategic vision aligns perfectly with C-Path’s mission to accelerate the development of new therapies. We are confident in his ability to propel the organization into its next phase of global impact and pioneering innovation.” »
“Assuming the position of CEO of C-Path is a great honor, coupled with a tremendous sense of responsibility,” said Dr. Romero. “I am committed to continuing C-Path’s tradition of excellence and innovation to transform drug development for the benefit of those who need it. This is a commitment that has been deeply rooted since I started at C-Path, inspired by the mentorship and visionary guidance of C-Path’s founder, Dr. Raymond Woosley. Our collaborative efforts will continue to transform drug development paradigms for the benefit of those in need. »
For more information regarding Dr. Romero’s appointment, please visit this link.
Cécile Ollivier has been a key figure at C-Path since her arrival as Executive Director in April 2021. In her new role, she will oversee global strategic initiatives with a focus on enhancing international collaborations and developing innovative approaches to address complex drug development challenges.
“We are thrilled to announce the promotion of Cécile Ollivier to Vice President of International Affairs,” said Tomas Salmonson, Ph.D., M.S. “Cécile has made an invaluable contribution to our European operations, and her extensive experience in global drug development and regulatory science makes her the ideal choice for this expanded role. His leadership will be crucial as we continue our mission to accelerate global drug development.” »
With more than 16 years of experience in the healthcare industry, Ms. Ollivier has made significant contributions to the development of medicines for pediatrics and rare diseases. Her efforts have been recognized internationally, including as an expert at the International Council on Harmonization (ICH) and as the leader of the global paediatric scale-up strategy. Prior to joining C-Path, Ms. Ollivier brought her expertise to the European Medicines Agency (EMA) and in the medical technology sector, focusing on the development of digital terminals in clinical trials.
“I am honoured to take on this new role,” said Ms. Ollivier. “The opportunity to further influence global health outcomes and drive innovation in drug development aligns perfectly with my passion and experience. I look forward to working with our talented team and partners around the world to make a meaningful impact on the lives of individuals and families affected by the disease and whose needs are not being met.”
